Eloxx Pharmaceuticals Inc. (ELOX)
NASDAQ: ELOXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELOX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $43.69M
- P/E (TTM)
- 5.63
- EPS (TTM)
- $1.90
- Dividend yield
- None
- 52-week range
- 8.20 – 23.40
- Day range
- 10.03 – 10.94
- Volume / Avg
- 14.98K / 28.48K
- Beta
- —
- Shares outstanding
- 4.09M
52-week range
ELOX stock today
On Nov 20, ELOX ended the session at $10.69, shedding $0.19 (1.75%), versus the S&P 500's 3.70% decline. At this level, ELOX sits near the bottom of its 52-week range of $8.20 to $23.40: 54.3% below the high, set on Aug 21, 2026 and 30.4% above the low. Eloxx Pharmaceuticals trades at 5.6x its trailing twelve-month earnings per share of $1.90.
Summary generated from market data by MetaCap's automated system. Methodology
About Eloxx Pharmaceuticals
Company profileEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Sumit Aggarwal M.B.A.
- Headquarters
- Arlington, MA
- Employees
- 10
- Website
- eloxxpharma.com
Financial highlights
Full financialsIn fiscal 2025, Eloxx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2013. Eloxx Pharmaceuticals reported a net loss of $6.0 million, compared with a loss of $3.1 million a year earlier. Diluted earnings per share came in at -$0.49.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $6.36M | $0 | — | — |
| Growth | -100.00% | — | — | — | — |
| Net income | $-6.00M | $-3.14M | $-17.05M | $-36.06M | $-66.73M |
| EPS (diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$38.25+257.81%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.49 vs —
ELOX news
All ELOX news- Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateNasdaqELOX, BF.A
- Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation ConferencePR Newswire
- Eloxx Pharmaceuticals Appoints Geno J. Germano to Board on October 19, 2026 and Announces Clinical UpdateNasdaq
- Eloxx Finalizes Phase 2 ADPKD Trial Design Following FDA Feedback; Appoints New CMONasdaqELOX, DDS
- Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORTNasdaqARGX, BOLD, CORT, ELOX
Eloxx Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GRMLGreenland Mines Ltd. | 2.99 | +2.75% | $44.31M | vs ELOX |
| INKTMiNK Therapeutics Inc. | 8.02 | -6.85% | $41.17M | vs ELOX |
| ELUTElutia Inc. Class A | 0.9001 | +11.12% | $39.96M | vs ELOX |
| IMAImageneBio Inc. | 3.92 | 0.00% | $48.83M | vs ELOX |
| TILInstil Bio Inc. | 5.23 | -5.77% | $35.47M | vs ELOX |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs ELOX |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs ELOX |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs ELOX |
Indexes, lists and sector
Eloxx Pharmaceuticals stock FAQ
What is Eloxx Pharmaceuticals's stock price today?
ELOX last traded at $10.69 as of Nov 20, 4:00 PM EST, down 1.75% on the day. Prices are delayed at least 15 minutes.
What is ELOX's P/E ratio?
ELOX trades at a trailing P/E ratio of 5.63.
Who is Eloxx Pharmaceuticals's CEO?
Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals Inc., which has about 10 employees.
What is the ELOX 52-week high?
The 52-week high for ELOX is $23.40 and the 52-week low is $8.20. The stock is currently 54.3% below its high.